<SUBMISSION>
<ACCESSION-NUMBER>0001144204-06-004944
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20060209
<FILING-DATE>20060210
<DATE-OF-FILING-DATE-CHANGE>20060210
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>06595332
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v035126_6-k.htm
<TEXT>
<html>
  <head>
    <title>
      6-K
</title>
</head>
  <body bgcolor="#ffffff" style="MARGIN: 5%; TEXT-INDENT: 0pt">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <hr style="COLOR: black" align="center" noshade size="2" width="17%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">FORM
      6-K</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <hr style="COLOR: black" align="center" noshade size="2" width="17%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
      OF
      FOREIGN ISSUER</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to Rule 13a-16 or 15d-16 of</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
      the month of February 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
      File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
      12
      BGC Centre</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
      The
      Esplanade</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
      WA
      6000</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form&#160;20-F or Form&#160;40-F).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
      40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      "Yes"
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule&#160;12g3-2(b): 82- ___.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PN" style="PAGE-BREAK-AFTER: always">
      <div style="WIDTH: 100%; TEXT-ALIGN: center">
      </div>
      <div>
        <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
        <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
      </div>
    </div>
    <div id="HDR">
      <div id="GLHDR" style="WIDTH: 100%" align="right">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant,
      pSivida Limited, has duly caused this report to be signed on its behalf by
      the
      undersigned, thereunto duly authorized. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>PSIVIDA
              LIMITED</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:&#160;February
              10, 2006</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;AARON
              FINLAY</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%">
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Name:&#160;&#160;
                Aaron Finlay</font></div>
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Title:&#160;&#160;&#160;&#160;
                Chief Financial Officer and Company
                Secretary</font></div>
            </td>
          </tr>

      </table>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="3">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>EXHIBIT
      INDEX</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a href="v035126_ex99-1.htm">EXHIBIT
                99.1:</a></strong></font></div>
            </td>
            <td align="left" valign="top" width="62%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Novartis
                to Co-Promote Retisert With Bausch &amp; Lomb</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">&#160;</td>
            <td align="left" valign="top" width="62%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
          </tr>

      </table>
    </div>
    <div>
      <hr style="COLOR: black" align="left" noshade size="3" width="100%">
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v035126_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
      EX 99.1
</title>
</head>
  <body bgcolor="#ffffff" style="MARGIN: 5%; TEXT-INDENT: 0pt">
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
      99.1</strong></font></div>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;<IMG SRC="psivida.jpg"></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 171pt"></font><font id="TAB1" style="MARGIN-LEFT: 18pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><strong>Novartis
      to Co-Promote Retisert With</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><strong>Bausch
      &amp; Lomb
</strong></font>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Boston,
      MA. &amp; Perth, Australia (February 10, 2006 ) -- Global bio-nanotech company
      pSivida Limited </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(NASDAQ:PSDV,
      ASX:PSD, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      today
      announced that </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">its
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Retisert</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;
product
      licensed to Bausch &amp; Lomb, will be co-promoted in the United States by
      Novartis Ophthalmics, a business unit of Novartis Pharmaceutical Corp.
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Retisert</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;,
      developed by pSivida, is the world&#8217;s first intravitreal drug implant for the
      treatment of chronic noninfectious posterior segment uveitis, a sight
      threatening condition that affects an estimated 175,000 people in the United
      States and an estimated 800,000 people worldwide. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      receives royalties from Bausch &amp; Lomb from sales of this product which is
      presently priced at US$18,250 for a treatment period of 30 months. This product
      is covered by Medicare, as being eligible for Medicare pass-through payment
      under the Hospital Outpatient Prospective Payment System.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      their
      announcement today, Bausch &amp; Lomb stated &#8220;Our collaboration with Novartis
      Ophthalmics will provide an expanded nationwide sales force, allowing more
      rapid
      distribution of this innovative technology to retinal specialists and their
      patients who are suffering from posterior segment uveitis&#8221;. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gavin
      Rezos, CEO of pSivida said &#8220;We believe this co-promotion deal will not only
      provide faster royalty growth for pSivida but also demonstrates the therapeutic
      value and market potential of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Retisert</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      copy of
      the Bausch &amp; Lomb media release is available on Bausch &amp; Lomb&#8217;s website:
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>http://www.bausch.com/us/vision/about/news/pressrelease.jsp?pressRelease=2006_2_9_retisert.html</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                Limited</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                Leedman</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                Relations</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                + 61 8 9226 5099</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
            </td>
            <td align="left" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                Jedynak</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                E. Janis &amp; Company, Inc</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +1 (312) 943 1100 ext. 12</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
            </td>
            <td align="left" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                Swallow / Helena Podd</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                Dewe Rogerson</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +44 (0)20 7638 9571</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="3">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
      TO EDITORS: </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is a global bio-nanotech company committed to the biomedical sector and the
      development of drug delivery products in particular in oncology and
      ophthalmology.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      owns or has the exclusive rights to use the intellectual property pertaining
      to
      BrachySil&#8482;, Medidur&#8482;, Retisert&#8482; and Vitrasert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      The
      company&#8217;s IP portfolio consists of 70 patent families, 74 granted patents and
      over 290 patent applications.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      owns the rights to develop and commercialise a modified form of silicon
      (porosified or nano-structrured silicon) known as BioSilicon&#8482;, which has
      applications in drug delivery, wound healing, orthopaedics, and tissue
      engineering. pSivida has granted an exclusive licence to its subsidiary, AION
      Diagnostics Limited to develop and commercialise diagnostic products using
      BioSilicon&#8482;, and has also granted an exclusive licence to its subsidiary,
      pSiNutria Limited to develop and commercialise food technology applications
      using BioSilicon&#8482;. pSivida, Inc., the company&#8217;s US subsidiary, develops drug
      delivery systems primarily for ophthalmic diseases and conditions. Retisert&#8482; has
      been FDA approved for the treatment of uveitis. Vitrasert&#174; is an FDA approved
      drug for the treatment of AIDS-related CMV Retinitis. Both of these are licensed
      to Bausch &amp; Lomb. Medidur&#8482;, a treatment for diabetic macular edema, is
      currently licensed to Alimera Sciences and is in Phase III clinical
      trials.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      conducts its operations from offices and facilities near Boston in
      Massachusetts, Malvern in the United Kingdom, Perth in Western Australia and
      Singapore. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      the
      Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      and in
      Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
      PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
      Lynch Nanotechnology Index.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company's largest shareholder and a strategic partner is QinetiQ, a leading
      international defence, security and technology company, formed in July 2001
      from
      the UK Government's Defence Evaluation &amp; Research Agency
      (DERA).&#160;QinetiQ was instrumental in discovering BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>(TM)</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      pSivida enjoys a strong relationship with it having access to its cutting edge
      research and development facilities. For more information visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.QinetiQ.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      more
      information, visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      document contains forward-looking statements that involve risks and
      uncertainties.&#160; The statements are indicated by the use of words such as
      "believes", "expects", "anticipates" and similar words and phrases.&#160;
Although we believe that the expectations reflected in such forward-looking
      statements are reasonable at this time, we can give no assurance that such
      expectations will prove to be correct. Given these uncertainties, readers are
      cautioned not to place undue reliance on such forward-looking statements. Actual
      results could differ materially from those anticipated in these forward-looking
      statements due to many important factors including: our failure to develop
      applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      due to
      regulatory, scientific or other issues, our inability to successfully integrate
      CDS&#8217; operations and employees; the failure of the CDS&#8217; products to achieve
      expected revenues and the combined entity&#8217;s inability to develop existing or
      proposed products; the failure of the Bausch &amp; Lomb/Novartis co-promotion
      arrangement to provide faster royalty growth. Other reasons are contained in
      cautionary statements in the Registration Statement on Form 20-F filed with
      the
      U.S. Securities and Exchange Commission, including, without limitation, under
      Item 3.D, "Risk Factors" therein. We do not undertake to update any oral or
      written forward-looking statements that may be made by or on behalf of
      pSivida.</font></div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <div>
        <hr style="COLOR: black" align="left" noshade size="3" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>psivida.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 psivida.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0JD17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#`V.C`Q.C,Q(#`S.C$Q
M.C(S``````.@`0`#`````?__``"@`@`$`````0```-B@`P`$`````0```$$`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```)=@````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"<`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54DEE9[CAY++ZG.`)!M;+BUP<=KOI;FJ'F,_L0]PBX
M`@3UUC$_I?UD@7HZJH=2ZUA=.<RJTNNR[I]##H;ZE]D<^G2/S&Q[[K/3HK_P
MEJI=6R6,R',Q<EWK,(^T5-L)V;F[J=S)_1;VC>CN<<7IHRF$NR;F,;ZCSN(+
MO`G\UL_04!Y\1RYL<H$?=X^Y.5_H</%'A']97"2`01J:0?9>M9['7]4RCTK%
M`W#$Q'C>&@!V[+ZBX?U_9B-I97_W(N1/JH[+LZ2+LBZR^JVVU^$^[^=^REQ^
MR>NX^Y[WU?I=[O\`!V*8Z6S,Q6U6O<:;73E-)<3:UI]M+]W^!?\`X?;_`#S/
MT/\`-J_EY>+@XUF5EV-IQZA-ECM`T<:JUBF9XXR(X>(<7"#Q;[:K.&I$V=.I
M3)+*_P"=7U=]>C'_`&A3ZV4UKJ6[N0_^:W?FU^I^9ZNQ$ZIF7U64XV.0Q]QU
M>>TD-'*;S&>.#&<DP2!0J/S2E+TQC%=&I&@07126;CNZG1EMIOG(I>)]0#1O
M]K3_`#49\?M*O]9+3M_HNL.T?[^5'#FN*(/MRB?<&*4,G#CE$G]+]V?^`GA\
M>EMQ)5,/JW3LZ[(Q\3(9==B.V9%;>6.ES-K_`.U6]9O4NK=,ZKT'-LP.K-Q*
MJX99U"J3Z3MS'=C7]*=GT_\`"*RL,@!>AWZ]G=267TW+Q,+ZOT963U`96/54
M"_J-A@6#CU7;B[Z:P.M_6OUNH="_86>U^+EY/I9;:PUQ(]3'9Z=K;&^K0[;9
M9_HTJ1+)&(L^&G7U/9I*EU/K72NDUMLZCDLQFOD,#S[G1]+96W<]VU3Z?U/I
M_4\?[3@7LR*9VES#,$?FO;])COY+TEW$+JQ?9__0]561U+)Q\C._9M!?9F5U
M>M8UC=S6-W#T?6L<6UUV7.:_T:W?SGIVH_7>J.Z9T]U]3!=E6.;1AT$QZE]I
M].BL_1]F\[[?^"WI=%Z4.F8I;98<C,R'&[-RG:.MN=]-\?F5-_FZ*O\``T>G
M6H\V&&;'+'/Y9BD"1$M.FI<B^FJC';57BNQ7/MLNO+I/J6V>ZRTV.)?8_P#K
M_P`W7^B_FU=G)R\?&QF8[Q4P-+K#`!VC3;)'L0_K!F4NNJQ*?UC+8'/?0P@;
M&D#;9DVN_1XM7\NW^<_P%=RU.FMM;AU&U[7N+&_0!#0(T#-_O_M/65#D\D^<
MYB.3)+@G#'<JA&>>,>'_`)OZ/N,G''A`B-OLBGIK]*IK)F!J?/NL;ZZ_^);J
M/_%#_JFK<6']=?\`Q*]1_P"*'_5-6Q&(B!$:`4!]&'+\D_[LGB>M8.'7_B[Z
M7EUTL9D/M!?<UH#W%POW[W_2?NV,_P`Q>A9&/CYF-0VZP,O<T&MTB27#7VGZ
M>Y<5@_5;K77>@=*H/4&#H^ESJ7,BVLRYCF5/9[;F>ZSTO5V>GZG^%7;YW36Y
M`K?2[TKJ=*W>0X;^][5%SL3+!*(QC->^.1X>*-ZU_7_=6<L")<5<`,8`?2+6
MQLC+PLMF%E'U*[-*W\G7Z,'_`*.QRG=_R]1_Q9_)8I4=-R'9+<G-M%KZ_H-:
M--/H]F_11GX5CNI5Y@<-C&[2W6>'_P#DUGPP<P<4(F,^"/,XYXHY")9<?+PE
MZN,_U6T2+^AOS>*ZIDCZO?6SK%V[TF=1Z<^ZCL#>!M9_:==7;_VXI5=/.!_B
MMN#A%F2P9#_^N65^G_X`VI;'UR^J-WUA=BV8UU>/90'LL=8"=S'[2-NS_1N;
M_P!-:77.C.S^@7=(Q'-I+ZV5U.>"6M#"PB=O\EBV+V:7M2O)II4N#_JCQOU@
M>YO^+3I0:8W.I!\X;:__`*IJ/]9.GX.%U7ZJ'%H927W5M>YC0TN#'XOI^H1]
M/;O?]);>9]4K,SZHT=!LN:,G&:PUW`$L]1D_2;]/TWM<ZM43]4/K%DW=)R.H
M]1INLZ9:QWI-80P5L=6_V60VRW(M]'])9:E:V6.7[MW&&O[O`?4O]9#T&GZQ
MTW.Q;NL]<?6&4].:0ZIK8=M?<VP&NEO\Y;_X/_PBK?XO&OKZUUZMU0QB'LWX
MS"'-K<'Y`]%CF^UWI?S:T.H_5CKH^LMO7.C9M..<JMM5XN87EH`KK=Z;/HV_
MS-=GN?5^D_D*Q]6/JSF]%ZCU'*R<IN6W.+7!\$6$AUCW/N_P>Y_J_P"#2Z+A
M"7NB7#52E]E;O__1[GZPW=0HR<*VC$HSZ"^&46W-Q[&Y(UQ[<:VZ66.]/UV>
MC_.*)P_K1U/3-R:^D8A^E1A$V9#@?S7Y]K65T?\`H-C[_P#A5\YI(L1KB-\5
M=?W?_5C])X6+]6JL4U8;L<T5V$6EMH?-WY_VBW>YUN3_`,>[UE?Q*\)@=]D+
M""1OV.W">W<KY=24']'][_)^_P#X'O?+_C_(RB^'3Y?^:_52J]39TZS`N9U0
MUC!<W].;G!M>V1_./<6M;[E\OI*9!JC>S]0=,9TZO`I9TLUG!:V*#2X.KVS_
M`(-[2YKO<K2^54DE"JTV?JI)?*J227ZJ27RJDDI^JDE\JI)*?JI)?*J22G__
MV?_M#V!0:&]T;W-H;W`@,RXP`#A"24T$)0``````$```````````````````
M```X0DE-`^T``````!``2`````$``0!(`````0`!.$))300F```````.````
M`````````#^````X0DE-!`T```````0```!X.$))3009```````$````'CA"
M24T#\P``````"0```````````0`X0DE-!`H```````$``#A"24TG$```````
M"@`!``````````$X0DE-`_4``````$@`+V9F``$`;&9F``8```````$`+V9F
M``$`H9F:``8```````$`,@````$`6@````8```````$`-0````$`+0````8`
M``````$X0DE-`_@``````'```/____________________________\#Z```
M``#_____________________________`^@`````____________________
M_________P/H`````/____________________________\#Z```.$))300`
M```````"``(X0DE-!`(```````8````````X0DE-!`@``````!`````!```"
M0````D``````.$))300>```````$`````#A"24T$&@`````#20````8`````
M`````````$$```#8````"@!5`&X`=`!I`'0`;`!E`&0`+0`Q`````0``````
M```````````````````!``````````````#8````00``````````````````
M```!`````````````````````````!`````!````````;G5L;`````(````&
M8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````
M````3&5F=&QO;F<``````````$)T;VUL;VYG````00````!29VAT;&]N9P``
M`-@````&<VQI8V5S5FQ,<P````%/8FIC`````0``````!7-L:6-E````$@``
M``=S;&EC94E$;&]N9P`````````'9W)O=7!)1&QO;F<`````````!F]R:6=I
M;F5N=6T````,15-L:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP
M965N=6T````*15-L:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,````!
M````````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````
M``````!"=&]M;&]N9P```$$`````4F=H=&QO;F<```#8`````W5R;%1%6%0`
M```!````````;G5L;%1%6%0````!````````37-G951%6%0````!```````&
M86QT5&%G5$585`````$```````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E
M;&Q497AT5$585`````$```````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO
M<GI!;&EG;@````=D969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E
M5F5R=$%L:6=N````!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453
M;&EC94)'0V]L;W)4>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P``````
M```*;&5F=$]U='-E=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`````
M````"W)I9VAT3W5T<V5T;&]N9P``````.$))3001```````!`0`X0DE-!!0`
M``````0````#.$))300,``````F2`````0```(`````G```!@```.H````EV
M`!@``?_8_^``$$I&248``0(!`$@`2```_^T`#$%D;V)E7T--``+_[@`.061O
M8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,
M#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4
M#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`S_P``1"``G`(`#`2(``A$!`Q$!_]T`!``(_\0!/P```04!`0$!
M`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&
M!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q
M0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$
MP]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G
M]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1
M\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C
M\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!
M``(1`Q$`/P#U5))96>XX>2R^IS@"0;6RXM<'':[Z6YJAYC/[$/<(N`($]=8Q
M/Z7]9(%Z.JJ'4NM873G,JM+KLNZ?0PZ&^I?9'/ITC\QL>^ZSTZ*_\):J75LE
MC,AS,7)=ZS"/M%3;"=FYNZG<R?T6]HWH[G'%Z:,IA+LFYC&^H\[B"[P)_-;/
MT%`>?$<N;'*!'W>/N3E?Z'#Q1X1_65PD@$$:FD'V7K6>QU_5,H]*Q0-PQ,1X
MWAH`=NR^HN']?V8C:65_]R+D3ZJ.R[.DB[(NLOJMMM?A/N_G?LI<?LGKN/N>
M]]7Z7>[_``=BF.ELS,5M5KW&FUTY327$VM:?;2_=_@7_`.'V_P`\S]#_`#:O
MY>7BX.-9E9=C:<>H398[0-'&JM8IF>.,B.'B'%P@\6^VJSAJ1-G3J4R2RO\`
MG5]7?7HQ_P!H4^ME-:ZEN[D/_FMWYM?J?F>KL1.J9E]5E.-CD,?<=7GM)#1R
MF\QGC@QG),$@4*C\TI2],8Q71J1H$%T4EFX[NIT9;:;YR*7B?4`T;_:T_P`U
M&?'[2K_62T[?Z+K#M'^_E1PYKBB#[<HGW!BE#)PXY1)_2_=G_@)X?'I;<253
M#ZMT[.NR,?$R&778CMF16WECI<S:_P#M5O6;U+JW3.J]!S;,#JS<2JN&6=0J
MD^D[<QW8U_2G9]/_``BLK#(`7H=^O9W4EE]-R\3"^K]&5D]0&5CU5`OZC88%
M@X]5VXN^FL#K?UK];J'0OV%GM?BY>3Z66VL-<2/4QV>G:VQOJT.VV6?Z-*D2
MR1B+/AIU]3V:2I=3ZUTKI-;;.HY+,9KY#`\^YT?2V5MW/=M4^G]3Z?U/'^TX
M%[,BF=I<PS!'YKV_28[^2])=Q"ZL7V?_T/55D=2R<?(SOV;07V9E=7K6-8W<
MUC=P]'UK'%M==ESFO]&MW\YZ=J/UWJCNF=/=?4P795CFT8=!,>I?:?3HK/T?
M9O.^W_@MZ71>E#IF*6V6'(S,AQNS<IVCK;G?3?'YE3?YNBK_``-'IUJ/-AAF
MQRQS^68I`D1+3IJ7(OIJHQVU5XKL5S[;+KRZ3ZEMGNLM-CB7V/\`Z_\`-U_H
MOYM79R<O'QL9F.\5,#2ZPP`=HTVR1[$/ZP9E+KJL2G]8RV!SWT,(&QI`VV9-
MKOT>+5_+M_G/\!7<M3IK;6X=1M>U[BQOT`0T"-`S?[_[3UE0Y/)/G.8CDR2X
M)PQW*H1GGC'A_P";^C[C)QQX0(C;[(IZ:_2J:R9@:GS[K&^NO_B6ZC_Q0_ZI
MJW%A_77_`,2O4?\`BA_U35L1B(@1&@%`?1AR_)/^[)XGK6#AU_XN^EY==+&9
M#[07W-:`]Q<+]^]_TG[MC/\`,7H61CX^9C4-NL#+W-!K=(DEPU]I^GN7%8/U
M6ZUUWH'2J#U!@Z/I<ZES(MK,N8YE3V>VYGNL]+U=GI^I_A5V^=TUN0*WTN]*
MZG2MWD.&_O>U1<[$RP2B,8S7OCD>'BC>M?U_W5G+`B7%7`#&`'TBUL;(R\++
M9A91]2NS2M_)U^C!_P"CL<IW?\O4?\6?R6*5'3<AV2W)S;1:^OZ#6C33Z/9O
MT49^%8[J5>8'#8QNTMUGA_\`Y-9\,','%")C/@CS..>*.0B67'R\)>KC/]5M
M$B_H;\WBNJ9(^KWULZQ=N])G4>G/NH[`W@;6?VG75V_]N*573S@?XK;@X19D
ML&0__KEE?I_^`-J6Q]<OJC=]878MF-=7CV4![+'6`G<Q^TC;L_T;F_\`36EU
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M^0/18YOM=Z7\VM#J/U8ZZ/K+;USHV;3CG*K;5>+F%Y:`*ZW>FSZ-O\S79[GU
M?I/Y"L?5CZLYO1>H]1RLG*;EMSBUP?!%A(=8]S[O\'N?ZO\`@TNBX0E[HEPU
M4I?96[__T>Y^L-W4*,G"MHQ*,^@OAE%MS<>QN2-<>W&MNEECO3]=GH_SBB</
MZT=3TS<FOI&(?I481-F0X'\U^?:UE='_`*#8^_\`X5?.:2+$:XC?%77]W_U8
M_2>%B_5JK%-6&['-%=A%I;:'S=^?]HMWN=;D_P#'N]97\2O"8'?9"P@D;]CM
MPGMW*^74E!_1_>_R?O\`^![WR_X_R,HOAT^7_FOU4JO4V=.LP+F=4-8P7-_3
MFYP;7MD?SCW%K6^Y?+Z2F0:HWL_4'3&=.KP*6=+-9P6MB@TN#J]L_P"#>TN:
M[W*TOE5))0JM-GZJ27RJDDE^JDE\JI)*?JI)?*J22GZJ27RJDDI__]DX0DE-
M!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O
M`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-P`N`#``
M```!`#A"24T$!@``````!P`(`````0$`_^$22&AT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#
M96AI2'IR95-Z3E1C>FMC.60G/SX*/#]A9&]B92UX87`M9FEL=&5R<R!E<V,]
M(D-2(C\^"CQX.GAA<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G('@Z
M>&%P=&L])UA-4"!T;V]L:VET(#(N."XR+3,S+"!F<F%M97=O<FL@,2XU)SX*
M/')D9CI21$8@>&UL;G,Z<F1F/2=H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R
M+S(R+7)D9BUS>6YT87@M;G,C)R!X;6QN<SII6#TG:'1T<#HO+VYS+F%D;V)E
M+F-O;2]I6"\Q+C`O)SX*"B`\<F1F.D1E<V-R:7!T:6]N(&%B;W5T/2=U=6ED
M.C0R,F,U931E+3DR,S`M,3%D82TX8C<V+3@P-F(P-V0W-6,W92<*("!X;6QN
M<SIX87!-33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R<^"B`@
M/'AA<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C0R,F,U
M931C+3DR,S`M,3%D82TX8C<V+3@P-F(P-V0W-6,W93PO>&%P34TZ1&]C=6UE
M;G1)1#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*/"]R9&8Z4D1&/@H\+W@Z>&%P
M;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"CP_>'!A8VME="!E;F0])W<G/S[_[@`.061O8F4`9$`````!_]L`
MA``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1
M"`!!`-@#`1$``A$!`Q$!_]T`!``;_\0!H@````8"`P$`````````````!P@&
M!00)`PH"`0`+`0``!@,!`0$````````````&!00#!P((`0D`"@L0``(!`P0!
M`P,"`P,#`@8)=0$"`P01!1(&(0<3(@`(,11!,B,5"5%"%F$D,Q=2<8$88I$E
M0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D@W23A&6C
ML\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>H
MJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$``@$#`@0$
M`P4$!`0&!@5M`0(#$00A$@4Q!@`B$T%1!S)A%'$(0H$CD152H6(6,PFQ),'1
M0W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58WA(6CL\/3
MX_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH
M>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1
M`Q$`/P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)3>V^MF];;:RV\M_;G
MPFT-K8.DFKLMGMP9&FQF-H:6!#)++-4U,D:<*O"B[,>`"?=D1I&"HI+'I)?7
M]EMMK+>[A=)#:H*LSD``#YGJHVL_F2=S?*?/Y78_\M?HBK[/P5!5SXC+?*7M
M@9#8_1&&K87999ML>7'U>8WY+$J$HB14T<A%M5N?9F+"*W`>_FTGCH7+'_-U
M$4GN3O?-,\MC[:;";J!25:]N*Q6R$>:8+2_*@`/17_E_V9_-+^"&U>N?D?OS
MY0]7=R8_-]I[)V!N;HG#]/4FUL374^Z\DE":?;68CSM9D*C(HA8JPB5_3J(L
M"/;\";?=EX8K9E(4FNJI_P`'07YKW'W3Y%M]NYBW7FVUNXY;J.)K9;<1IW^2
MG62Q/"N"..:4ZV+<365&0Q6,KZN@FQ=578^BK*G&5+!JC'5%331S34$[!5#3
M4DCF-C8793Q[)"`"0#45ZR+A=I88I7C*.R@E3Q4D5(/S'`].'O73O7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=?__0W^/?NO=8:BHAI*>>JJ'$<%-#+43R$$B.
M&%&DD<A06(5%)X%_::]O+;;K.[W"\E"6<$32.QK1412S-BIPH)P*];52[*JC
MN)H.@KVSWKU)O"NCQFW]\8BLR$S:(:23[JAEE?\`"1&OIJ9)7)^@4DD^X$Y&
M^]9]WKW'W6'8^4/=';[G>)#186\6!V/D%\>.(,3Y!223@"O1I<['NMI&9;BR
M<1^N#_@)Z$7-9S#[=H)<KG<E1XG&P-&LU;73)3T\;2N$C#R.0H+N0!_C[F7F
M7FGEWDW:)]^YJWJWV_9HBH>:=PD:EB%4%C@%F(`]3T7PP37$@B@C+R'R&3TD
M%[;ZR8!EWSMI@?H1DZ<@_P#)WN.!]XCV-8!E]T]E(/\`R\ITL_=.Y_\`*#)^
MSH).[>_LKMG8.5K>@]OX#NOM>0Q4NU>OTW5082#)ULY*K)7Y&9S)3T,)L7,:
M/(1^D'V;[%[X>RW,&[V&QV'NELS[I=2+'#$LZM)-(QHL<2CXG8\!BO1#S)#S
M/M>TW-YLW+DMY>H,)70H_I.QX*/.E3U6U@?@/VE\AZ_'][_S8.WZ#=V-Q58F
M<VU\4-G5U1AOCSL%H9!)CHMT1%Z=^RL]`@(D:I@*,UK%_H)$YIYXY7Y$V2\W
MS?=VMMMV6`5DN9W"`?($\2:85:L?(=1/M?MIS!SE>P;G[C;@UV^L-%M\-1;1
M4X:P*>*W\6H4^9ZM:ZN[`Z1J:6GV!U1D=NTF,VKB0*/;VW\7-A\1A\11A8PM
M+!]C1T-/2P!APEA^?<.^W?WD?9;W=YAO>6O;SGVWW7?((3+(D<=PM$5@K-JE
MB16`9@.UCQQU-[\OW&QV4*G;UM[%1I4#2%4#R`4X_9U5[F=O5O\`,B^;VV<S
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MP0&21R%4%F`Y_)]E>^;[LW+6UW6]<P;G!9[1``9)IG"1H"0`69J`5)`SYGIR
M.*29UCB0M(>`&3U!PFYMO[D2>3`9G'YB.E=8ZE\?4QU*PR.NM4D,;,%9D-P#
M^/97ROSQR?SM%=S\H\R6>XPP.%D-O*L@1B-0#%2:$C(!\NKS6UQ;%1/"R$\*
MBE>GSV*NF.O>_=>Z:\WF\1MO$9+/Y_)4>'PF'HY\AE<KD)TIJ''T-+&9:BKJ
MZB4K'#!#&I9F)``'O8!8A5%2>FIYX;6&6XN952!%)9B:``<23Y`=!QUSWWTM
MV]69'']7]H;)W[78F*.?)TNUL_09B>AAE8K')51TDLC1([*0"?K;W=X98Z&2
M,@?/HMVW?]DWAY(]KW2"XD3X@C!B/MIT+?MOHWZQ33PTT;35$T4$*6+RS2)%
M&@)L"SN55;D_D^_<>M,RJ"S$`?/K'35E'6*S4=7352H0KM33Q3JC$7"L8F8*
M2/P?>R".(ZJKH]=#@_8:]2?>NK]>]^Z]U[W[KW7_T=_CW[KW7%T61&1U5T=6
M1T<!E=6!#*RD$,K`V(/!'NDD<<T;Q2H&B8$$$5!!%""#@@C!!XCKP)!!!SU6
M]\K-B8U,G55&%HAB9L3CZ7,8D8N39>$HJ.L@">6<JU=2;BG<\N!'"R^2VGWQ
M;^_M[6[+:;]>[ARQMPV^XL+2*ZMEM6V:QABD0+K8@SP[BY.7`CA8"324X`]2
M)RO>RM$JS2:U9BK:O$8D?L*#\SPZ,KTIF<=WATE@#O:@H\]JC_AV8I:^%*B"
MKJ,14-#35,T<H.J62.%)"3SKN?>;7W9N9-H^]!]V;E?_`%S]GMMT:AMKN*=%
MD262SD*12N&KJ=E1)"QR7);SZ#N\Q2;+O,_T4A0<5(Q0,,@?X.JR?D5M?;6U
M>W-R8?:^/I*#"Q"DEIZ2D"M2PR24L)J$@L6556;4"H/I-Q[X>??6Y%Y7]N?O
M#\[\L<F[2MAL41A9($J$C+PH[!`3VJ6)-/*O4D<MW4M[M%M<32:Y#7N]:$CH
M[WQ!ZPV%7==83>M;MG%U>Z(LS55$&8J::.:KIIJ0Q?;O2R."8#$3<:;<^^I/
M]WE['>U.Z>SO+7N1N?)=G<\[1;G+)'=RH))8GA*^&T3-704XC32AST"N;-RO
MDW":T2Y86Q0#2,`@\:^O05?)C<E9V'W3C>M7FJ?[L;6IX:RNH:>NQ>/>JKV!
MEJ9B^9JZ/%320)XQ$LKWY:WU/O'_`.^]SONGNW]Y79O9@W<XY'V.)))X8KBU
MMVDG(US/JO)H;5F5="QK*]:%Z?$>C7ENV2PV>3<=(^IE-`2&-!Y#M!;UK3Y=
M&#3JG(;TZ;H]G[=R*[/?>U'-CMW;TQM/@:7=5)M:=E6NQ.'KMM//0FMR$`\"
MRK*42)G-PUO?4#[L7*&P<N^VW+F]0;/;#>YXF+3^!MZSE"1IC>7;S)`Z+04T
M2LII4YZC7G*&]W?ZK:X;QHK:3M=@SU"_BT!J$,PQ4@4%>A^ZUZUV1U!LC;W7
M77.W<?M;9^U\?!C</A\;"D,,,$"*AFG<#R5=;4%=<T\A:6:0EG8L2?>14DCR
MNTDC5<^?2#:]KL-FL+;;=MMEBLHE"JH]!YGU)\R<DY/2RJJNEH8)*JMJ:>CI
MH@#+4U4T=/!$"0H,DTK)&@+$#DCD^Z=+6944L[`*/,X'4&'/X*HHZG(T^:Q,
M^/H@QK*Z')4<M'2!$$CFIJDF:"`+&=1U,++S]/>Z'`IGJ@G@*-()D\,<344'
MVG@.HV!W5M?=4$M5M?<F`W)302&*>HP.8QV8@AE%P8Y9<?45$<<@M]"0?>V5
ME^)2/MZI;W=K=J7M+F.5`<E&#`?F">@'^4G;.3ZKV!%)M]UAW%N2L;%8RJ<!
MOLHE1&KJR-#<-/!%*NBXM<W]X2??L^\%O'L)[213\JS+%SAO,[6UM(P!\)54
M-/*H.#(BLNBH(!-2,="OEG:H]TOR)Q6WC%2/7T'V>O5?^Q.E.Y^Z,)7[YHMP
MU$D!J*F."HS6:KS5Y:JIK/,E(!(YC4,P"EM*DG@\>^1/M/\`=E^\Q]Y7EC=?
M=+;^;I7MO&E5)+R\G\6YECH76(5:@!("EM"5PO`]#V^WG9MGG2Q>W`-!4*HH
M`?7_`%5Z7?QV[KW[L+L:#K'><^5RF*K,JV#KJ'(&IR&0VWE$+*DT<UIYEI`R
ME72X0Z@1]/<N?<U^\K[N^U7O#;^R/N7/?WNP3WS6<T5PTD\VWW`8J'1CXCB-
M6!5XE)6C:A32.B_F'9["^V\[E9A5D"Z@10!Q\^&?0]6*=N;(3L;KW<6S7RD>
M&7-4\$)R4T:21TWAJZ>IU,DA",&\.GG^OOL7]X/VP7WC]H^;?;I][CVY=PCB
M'U#C4L?AS1R@D5'$I3B#G!Z`&U7O[OOX+L1E]!./6H(_R]!U\>.E8>EL5N2A
MCW-3;B3-9"EKC+!##`M(*:E\!C?Q&QU?6Y^@]P_]T#[M$/W;]GYRVV'G.#>!
MN5U%+JC4#P_#C*Z6RU2:D^6/+SZ7[_O)W>2W<VYCT*1GSJ>AUI-Q;?KZG[*A
MSN'K:S]S_)*3)T534_M7\O[$,[R_M:3JX]-N?>9-#Z=!I9X';0DR%_0$$_LZ
ME5^4QN*B6?*9&AQL+N$2:OJZ>CB9S]$62HDC1G/]`;^_`$\!U9Y(XQ61PH^9
M`_P]`UW]U_C._>@.VNK:3=..Q5!V1L/<VS6W1$]'DJ'$?QK&S43UT@UR4LRT
M@FU,K&UOK[=@D\">*4K72P-.B3F/;$YAY>WC:$N51+JW>/7@A=0I7T-.JIOY
M4/\`*@QG\O3?G:.[J'OC"=MOOW"8O$OC\5B\90OBEH*F><3S/1$NXE,MK&PX
M]K;V^^IC5/#(H?0?Y`.HS]L?;`<C;A?W@WI+KQ8]-%U&F:U.IF_E3J[_`".2
MQV(HJC)9:OHL7CJ.,S5=?D:J"BHJ6(6!EJ*JIDB@@C!/ZF8#V6@$D`#/4SR2
MQPHTLTBI$O$D@`?:3@=54_SBM\B3^63\DMV=<;T834F%VV:+=&QMQ#S4K_WS
MV_#-]KFL'5L8&9)"CZ9`;-8_7V8;8G^/1*Z^1XCY'UZB;WEO_P#F&7,%WMMY
M4CPJ/&__``Z,$:D/GP.>!IU7A_PF:WIO3>G37R=JMZ;RW7O&IHNTMIP451NG
M<&4S\U'`^SXY)(:27)U-2]/%))ZF5"`3S]?:_?T5)(`HIC_-U'7W8=QOMQV7
MF:2^NI)7%S&`79FIVGAJ)IULS5^1Q^*I):_*5U'C:&`!IZROJ8:.DA4D`-+4
M5#QPQ@DVN2/9``2:`5/63TDL<*&2615C'$D@`?F<=)_`[]V+NFHDI-L;TVGN
M.JB#-+38'<>'R]1&J?K:2''UE1(@3\DCCW9HW459"!\QTFM]QV^[8I:7T,KC
MB$=6/[`3TK/=.EG7_]+?X]^Z]U[W[KW1,_DSB7?(15*T+3K7[<R$'W(Q^TGC
MCFA1PD3UV<I9,@DF@:K0R`JO(Y`/OFG]^/EZ27=8;]-J:6.ZV2X3Q!;;2P61
M`0JM<7T37"M3N`A<$+4K1@#T,.6Y@$*EZ4D&-4G#[%-/VCJN'<M/\NNS^CMK
M_&_XCUF+V:W:6]L]MGO'O"KK+Y/IGK^7#S3U];M>ACG62JS^?IU>DI9E5_#/
M,K`J1J%_[J7>]IN?9;G3:;BX_P!VNV;WF&HJ5EC#!P,U75BH.FM>/#J/_?6V
MYOOKK9MFY64107Z,L]SYP1CX@N00S+4`@$U(II^(2>UNO*/J+/X7JN@S&8W%
M1]?[0VYMR/<6X:AJO/9Z6FQM,]7E\Q5,S--7Y"LDDE<W-BUKGWS+_O%9_JOO
M6^XMR5IXAMVIZ5MX\>74Q>W6VILW)NQ[1',\B6T6C6YJS4)JS$UR34\3U9Q\
M-_\`F2.'_P"UGDO][A]];/[N/_Q&;8?^>^Y_PIT%.;O^2S+_`*4=$QS5;!G_
M`)']F96B"9&C@JZVDB:)-OU8<"*FA1DI]Q1U%#(I>-A=5UK^+>^9W--[#S;]
M\_WHW_;D6\VI;FXC0JNWS!A2.($)N*R0,-2-E5UK^$BIZ&4"F#EW;HG[9*`F
MI<>IXI0^?V=6B]>T#8S96VZ-X33R1XNF,L+4M%1.DCIK97IL=%#11.-7(C4+
M_3WW9]G]H?8_;+DO;9;<Q3)81ED,4,)5F%2#%;JD*$5H1&H7T'49;A)XMY</
M6H+'S)_F:G]O2R]R3TCZK"_G+5M?COY:_P`GZW&9#(8NN@VM@'IZ_%UU5C:^
MG;^^FVP6IZVBE@J8&9202K"ZD@\'V8;4`U_;JPJ"3_@/45^]<TUO[9<SSV\K
M),L<9#*2"#XT?F/Y^HP>M63^5/\`%GY0_P`PKJ+MSIK'_*[>G4/1&U]X8C<F
M\(<=E<YE]X[QWG7[=@H*&BDR-1D/+#MFCQ:H[TY?QR3`^FY)]B#<9+6Q:)U@
MK)2G^7SZQ=]I>7N;O<3;MZVUN:'M]E2<.XJQ9Y""H&".T*,@FA/E7/2*^"F^
M^[/Y='\UG!?':KWSF<K@)NX:+I#L/"-ELC+MG<N-W754=+A]QG$5E1)2P9&A
MBRT=4L@19%EN+V]N7<4-]MYN`E#H+#UP*X_80>BSD7=M\]N/=:+EF:^:2`WJ
MV\B@T0B5@NH@TJ1J5E]#Y^NZ_P#+GJW,=C;`HJ[;L#UN:VC6S9.''1B\M=15
M$<4>0C@`NSU"10`HH!+<CWS-_O#?8?F#WG]I-NW/E&T>ZYEY>N)+A+=/BFAE
M15G"#BTB*BLB`$N:@9ZZ9<J;I#MU^ZW#:890`3Z$</RSQZ)AT-\F\KT]3MLW
M<.'DRFUXZ^:62)!]OF\'43,JU*+%,4$L"LES&XU"WIM<WYI?=.^_%S!]W"T;
MVUYWY;DO>1UNW8J`4O+21B!(%#T#I45:-Z%2*(021T,=]Y:BWAOK+:8+<Z1\
MU8>7V'Y_MZLJZ^S75V_J>;>>RX,!7U5?*)<C6QT%)'FX:H@G3D0\0KH)OK;5
MPUN"??;7VAYG]B_=FRF]RO;.UVBZOKM]=Q,MO$EZLI\KC4@G1^-"]-7%21U'
M%_#N=BPL[QI%51@5.FGR\B.DG\HI9H.B]^RP334\JT-%HFIY9()D)RE$"4EB
M9'4D&W!^GN/?OTW5U9?=;]TKFSN9(;E8+>CHQ1A_C<'!E(.1@YR#3I7RRJMO
M=D&`(J>/^E/0"?!"IJJW;78/WU75UW^YS&H/O:J>KLC8WU*OW$DEE:_('!]X
MG_W4N[;INW)_NQ+NFY3W,B[E;`&61W('@MPU$T_V.CSGB.-+BQ"(`"C<!\^M
M36@RV\_@A_/1HMK5^\]XU.SJKO&.AI*3+[HSM9AWVUW@:1XRM#65\U$])C9M
MTE$]!$?B'T(]]E_"CN]K\15&OPS_`,9_XKKFFNY;AR)[WKM\]Y*;+]X*HU$Z
M=%SP_(>)3[5J<]'G_P"%.7?N:PK_`!KZ6VMN+-X&K5MT=EYM]NYS)8>JKJ&>
M!,+AHJJ3&55,\M-%6X^9D#$C4U_:/8K=76:5TJ*T_8"?\W0[^\US+<6DG+FR
MV-XT4X5Y6TL14.5C%0#D"C$5\S4=6:]<]4YOHK^2-E=HY3)YX[PB^*V[MR[@
MS%=E\K-FWS^X-OUN6>J7)5-2V1@DBIYX5C(D!4("+>T19)-V32H\,2``?(>O
MKU)EM87FT>R%W'<S/^\3M4LCM4@ZW4MVFM5`%`*>G5/W_"9;<FYLYW3\D(\[
MNC<^>B@V?MMH(L]N+,9J*!VR-:&>&+)5E2D3L!R5`)]F&]Q1QP0E%H2W^3J(
M_NU;G?W^][^MY=O(JP+0$GB6.?MQUB_X4C_*/L^7N_K/XK;4W/G=N['HMH4>
MZMSXK!9>LQ:[MW!NC(0T6"BS#4,T$L]!0P>1?`Y,3E]14D`BVQVT0A>YD0'.
M#YBE.D_WD^:MW;?=LY3VZ[>.W6(.ZJ:"1I`:%O72`0`<5-:5`Z"7OW^5W\H/
MB!_+CW7V_A/E9F<YU[O38VSLWWIT-EUKY=KG'9W)8*MQ\&UA5S5,5/E\/EZB
MG6:8+&TBH]C8V+MO?V\^X"-K?N!-#]@-?LJ/MZ*.9/;+FGE3VPFW2'FAC8S0
M1-<6^0M'9"M`:@LKE:D!3C!ICH^?_"7>W^A3Y36^G^EC:-O];^YD=O:7F+^V
M@IPH?\G0X^ZI7]P\SUX_4Q_\</11OYC3?S)_G]\WI^@-G;([FZR^/N'WM'L+
M9N2@P^\]O[!FHD>&++]A[TS.*@HX,U3K))*\2-(\?@11&-7/M^Q^AL[7Q793
M+IJ<BOV#T].@Q[D-[E<_<[#8-OM+RVV)9A&A\.18=-:-)(P&E\U:ODM`!7/1
M(?GC\!_D9_*'W)TUV/L_Y&YS+C?.0R$6!W3M3(Y_;M;C-V;:IJ3)Y&BR6-:M
M^TRF*FCJ8RBS*ZRJ2)%//M9975ON:R1O%D>N>-?\W0$]P.1>9O9^?:-RL^82
MR3L2&BU1L'C*E@:UQW`YP14$=;L_\O[OG</R;^&WQ^[QW=%30[LW[L''Y'<L
M=&A2F.:IIJG'5LT*FUEJ7H_+QP"Y'L)WL*P74T2?"#C\\]9O>W^_7',W)VP[
MW>`?5SPU>G#4I*DC[:5_/K__T]_CW[KW7O?NO=5.=G_-3_2U\S\#\)_C_P!6
MT/<TNRJ6HS?R/[2EKS3[7Z,@JJ22/#T$%6DJ4N8W3+6S0BHH@SLD;.A76"5!
M'N7[5;#[E<J7-CO4$(W)%9K*656=89RI"NR*REU(PRGBI/#!Z`,/N3=+SU;<
MK<M6`NX8LWT@:@A7^%6X%@:5S@]H!(-%?/TC\F>NMX9'=?7\NWV^\_:JTV]5
M18W'9.GB:\0K,)D9)R78*"2O(8\'WQXG^Z]]]CV=]Q=UY_\`:A]HU7`"RC;I
M(X8+A%\GL[ER36@."2#P(ZR&&]<N;A:):7WB4'#6"2/]LO14>WZ[?.2W[EJO
ML>AAQN[G2G7(4E.H6&-4@C6$HJDJ`T04\>^>_P!Y7=/=#>/=SF.]]X=L2TY[
M;PQ/&JA56D:A*!684*4.#3H5[,EE'81+M[ZK;-#^?0X=5'Y-9GKF#;/6-'!2
M[0J)JJ./,)44E%5EI;"IB2KJ;B,$<76S#\'WEG[!/]]SF?V6AY+]EK`6_(TT
MTJBZ5H(9"6IXJB>5ZJ#PJH##R/1%NO\`5N#<3<;B];D`=N2/E@=&/Z+^-NZM
ML%'[%BVI-0++-5/04<=35YJKK9&61):_,+4>&2*-P3I4<W]YE_=9^Y5SUR.8
MI/>2VV&7;!(\K01"2:\EF8A@TUVL@0HI%=*C)Z#N]\Q6US4;>TH:E*F@4#Y+
M3H\2J%554650%4#Z``6`_P!@/?49%5%5$%%`H/L'0+Z[]VZ]U5S_`#HO^W9_
MRD_\-3`?^]KMOV8[3_R4;;[3_@/43^^/_3K>:_\`FE'_`-78^J@_^$N7_'B_
M*/\`\.[9_P#[SU-[,^8?BA_U>740_=8_W"YH_P":J?Y>JQOEEI/\_G)Z+'_G
M+KI[]/\`JOMMC7^GYO>_^/LTM2?W*E?]]-_S]U$G-V?O!W=.'[ZMO\,'6^1N
MKL'9>QH89-U[CQ>$,T;24\-;51Q5%0J#UF"`MY9M/YL#[Q_]P/=[VT]K8(I^
M?^<[#:_%!,:32JLD@''PXR=3T_H@]='+2PO+TTM;=GIQH,#[3T"F]NDNIN_]
MMP[LPD=-19'+T9J<1NO#Q+323GU"(UU-H$53&SCUZE$MO[7O&3W/^[%]W_[V
M_)<'/G+<$-MO&X6_B6NZ6BB-G.=/U$5-,BEOCU()?Z?1U9;SNNPW)M9B3&C4
M9&S^P^7^#JNS8.4W3T+WA3XAZHK-C]QQ;>W#34LC_89BAJ)A!K,=R&#%E=&_
M4MK7^OOC5[2[_P`]?=*^]%:\M3[D^NSWA=OOHHF/@7<,DBQY4X*G4LB-0,I%
M`15@9"OXK;?=E:8)\4>M2>*D"O\`L=67?*;_`)D1O[_J`HO_`':4/OMQ]_/_
M`,14]U?^>>W_`.TN#J-^6/\`DN6/VG_CIZ`+X#_\>UV!_P!K_&?^ZWWB/_=*
M_P#*F>[?_2SMO^K#='W/?^Y%A_I&_P`/6N'_`,*6>H\AU]\@_CI\GMKTQH9,
M_@GVW4Y&%2K/O;8^4J-RXFJ:1`I,D>-2G4<ZK(+>^T.Q2!X98&%2"?V$?YQU
MSP^\SM$NW[_L',]J0BR(JEO^&QO4'\D8?[R.B;=X[_H_YH_\TOXX8+;TLV2V
MADL?TULFN,H:2.#!;>Q^(R&_JDQL7'C%=55C,+>H_7VLCC.W6$I8T;N(^WR_
MR=`C>=RA]U_=#88+4>)9D6L+$Y`0*#*?R/B'K<]^<F.I\1\%ODEB:0!:7%]`
M[UQU,H`4+3T6UZBFA`4<*!'$.!]/85LC6]MR>)<?X>LTN?XEA]O^9X4^!-ND
M4?8$H.M87_A,%_S.OY*_^&;MK_W95WL_W[^P@_TW^3K&'[KW_)<YA_YYU_X^
MW1>O^%"%O^'-ML7M;^XG3.K^EOXVOU_P]O;-_P`DX_Z8_P"$=!O[P'_3V(/^
M>:#_`(Z_6Q=_-NM_PS]V_:UO]&76MK?2W\>VG:UN+>R3;_\`DIK]K?X#UD;[
MN_\`3G=R_P":%M_U<CZ(%_PEV_YDI\I?_$K[0_\`>,C]KN8?[6#_`$O^;J/?
MNJ_\D'F?_GJC_P".'I5?S#/YWF^\'W%4_#WX!;)7L3NA=P_W.S>^ZJBGRE#1
M[E+K#+@=EXF$A<GD*"=M-363K-20D,I2Z,?;5GM*F/ZF[-(Z5I6G[?\`8Z,_
M<'WPNX-Y/)_(=KX^\>+X32Z2]'K33$@H"5."S&G$4-#U1W_-'^-/SWZIV-TM
MW'\\N\O](V\>V-Q[HQV$Z[7(_P`23KV3%8C&9*KG:7'+3[;26KIZY("M+"K+
MXK,Q`'LYVNXLW>:.UAHHIFE.-?S_`&]0)[O<K\_;7M^Q;SSQOAGNKEY`(BVH
MQZ0A).D",5U`448I0D];=W\F+_MV?\4__#"D_P#=UD_88W3_`'.G_+_`.LQ/
M9?\`Z=KRQ_S2?_JX_7__U-_CW[KW53/\T'YI;WZ3P>QOC%\:<>=T?,7Y0UDF
MT.J\1!']Q'LS!5!:GW)V3F=)M!2[?HBYA#:29#K!_;Y,+&V637/+B!,GYG_5
M_F\^HJ]R^<KO9HK'EGE]/$YKW-M$2C.A#\<A^8'PC[7X*>C$?`?X5;-^$'1]
M#U]BJEMS]B;EJWW;W+V97L]5G^QNP\IJJ,SF\GD:@"KJ*6&IG>*C1_\`-4X`
MMJ+$LW=TUU+JI2,84>@_U<>C_D3DRTY+V5+%&\3<93KN)CEI93Q))R0."US3
MC4U/1WO:7H;=4N_+J>GI>Z]Y5U;54]%04-#CZFMKJR9:>DHZ:+'4S2U%1,YT
MQPQJ"6/X`]_,]_>"Q37'WJN=K6V@>6ZE^E5$0%G=C;Q`*JC)).`.IAY7>.+8
M(9YI52!`Q9F("J`34L3P`Z,Q\&^RLCOWJ[!T^P]OY%]CP9"OGF['SE)-C\)G
MD\OC:+9=(]IL[1R/$5%:'6)&!]!]]I_N,^WO-_MQ]W3EG9N>]FEV[?Y9Y9Q;
M2XE2&72T;2*<QLP%=!R`0?/J'=VYHL^9M[GGY>)FVA>TW)!$;E:@B'^-:XU@
MTKY=6%>\NNM]>]^Z]U[W[KW57/\`.B_[=G_*3_PU,!_[VNV_9CM/_)1MOM/^
M`]1/[X_].MYK_P":4?\`U=CZU1OY1?RZ^47PPZZ[V[6ZI^.-7\ANCUR>"I^T
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M.9[$>25(QXB>`U_Z^^='WY_NS7GW@O;NTN^58E//^S,\ELI.D7$;A?%@)X:C
MH4Q5(`:H/Q==*^6MY&U79$Q_Q63#?(^1_P`_1!=B]Y]P]%4%=LA<+IIXJB<P
M8O<6,JVFQ-7(=,AHS'-`3"6`(0ZE_I[Y(>UOWI_O(?=5VO=/:X\O*+9)7*6^
MX6TQDMI7PQB(=#I)%=!U)7(P<CR]V/9]\DCO1-DC)0CN'SP>E#TOU#V%W!V7
M2]@;MQ]=2X,9W^\.;S61A>E_BM7%)Y5H\;$RDO>6W/Z45;?GV-/NT?=T]W_O
M$^]UI[O^XVTW,/+!W(7]Y=SQM$+F17UB*W##N8L%R`411D\.D^\;OM^T[:VW
MV<@,VC2J@UTCA4]'[^3]/4571N_(*6GFJIY*&C$<%/&TLTA&3HB0D:@LQ"@G
MC\#WUG^_19W=_P#=<]TK6QM))[IK>WHD:EV-+N`FBJ"30`DT!P.@+RRRKO=D
MS,`M3Q_TIZ`CX)8_(8_;F_DR%!64#R9W&M&M9`\#2*,:`60.`64'ZD<>\4O[
MJG9=WV7E#W8AW?;)[:1MRMB!+&R5_0/#4!7B.&/SZ/.>)(Y+BQ,;@C0>!KY]
M$\_GZ_'O)=Y_`[.YC;6%K,]O'J/=NW]\8''XZE>KR$U)+60XG<8I(HP9&D&&
MJ9&*@>I5(]]>]EN!!=T9J(RFOY9'6*?W@>6Y.8.0Y9+6W\2]M)TD04J:,0CD
M?8I)ZH\_X3H?&/>.0^86\NYMZ;(W!MS%]2]93Q827<^$JL;'5YO?DM5B76@%
M7%HFJJ*AI"Y((,88'ZD>S;?;I6ME1.#$>GED^?V=05]VSE&[3FV\W:^MV46D
M#4U*P!,E46FI0"P`;Y@&N*CK;)^=U)65_P`,_D[18^CJLA7572N_H*2AHH6J
M*NKGDP-6L<%-`GKEFD8V51R3[#EB0+RV).-8_P`/66WN"CR<C\U1Q(6D-C*`
M`*DG2<`=:RG_``F@V3O;:O<_R.FW5LS=.V8*K:&W(Z:?/X6KQ<51)'D*QGC@
M>I11*ZA@2!>WL\WN17@BTG@>L:/NT[=>6.][^;F!E!@495AD,33('KY==_\`
M"D3XE]J3=N=<_+79FU\QN/8HVG1[2WKE<)12UTFT,YM_(15FW:S*00*TB8VK
M@61O/PJ,FD_4>]['<Q>&UK(<UQ^?^R/MZK]Y+E'=_P!\6'..W6S26PB"2,`3
MH*5"@TJ>X$T)%!3)'06;]^?7S@^?_P#+ZW7T5L;XMU%!U_U]UYM^A[N[LK#6
MST.X<9M>JPZX^CV;0R)$W]Y\E7T,$DL*O,WC\A``]NI:6=I?^)),0Q)TC'G7
MYU_:!T5;CSWSQS][;S;+9<MJ+*W@C%S/WG4(V33I!4`,6`)"LY(J:`='O_X3
M,[3W9MWI'Y1TNY=M[DVC49+LS:LE!_'L54XNIDB;94:?<TL=4J&7P.XN1P&%
MO:/?I%>6W9>%#T._NQ6%W8[)S3!=1LDAN4H:,/P'(U`5XC_B^J&Z#<W?7\K3
M^97N3M7>W3N2W%N+;W8G9]5C<1F\?4R8S?.V.P*_+>/,[;S(BDB>NEQ6562&
M=0QAGX(.DCV<E8=PL!&LAH0.%/D?Y<,]0(L_,'M7[GS[O>;3XDR3RD*X:CJX
M9=0(!!+!M2LM:'B*UZ'S^:5WS\\/GGLOIOM[?_Q<W1U3\?J;<6XZ/J';<&,K
M<INS)9VIQ=!_&=PYBR+42XJKH?%%3S"**%GB<`7!]L;9'9V;RHLM9<5R/F!C
MA_,GH0^[F\\^\^6.R[G>\O&VV'6X@`5R2:*68L0&(8``'0JU!`)/6U;_`";J
M.NQO\MSXOXW*8^OQ.3Q^R9J6OQN4I):&OHZE<QD7:&II9@)8G"2*;$`V/L.;
MF0;V8CAC_!UE?[-QO%[<\N12*1(L;`@@@_&QX$`\#Y@=?__5W]9)$B0N[!5'
MU+$*+_0"[$"Y/`_Q]^ZT2!DGJC[^7_U5N'N7YS?.;YK=VX>M7>.U.T\U\;>C
M<9F:8QIM'K+8U744E;6XVEGBTQ5&<GI8&%5'S*A<W]1]FUZXAM;6VB/:RAC]
MI_U?X.H0]O\`;;C>N=^>.<=ZA_QN&[>TMP1\,49(K0@9H%`(]6H>[J\-F5%+
M.P55%V9B%4#^I)L`/93U.%:9/#JMOY*?S0?CUT3NB'J+91SGR)^1^8=Z/;70
M_2]*-T[IJ,D2$@7<5?3,^,VMC?*P\L\[LT:@GQM:WM?;[?/.-;42'^)L8^7K
MU&W,ONAR]L5R-ILM>X\Q.2J6UN-;EJ5`=AVH/F>'IU7/N_KG?G;V\JGMOYH)
M39O>%;/39#;OQ*V%4U]7U)UPT*QMCI>V=QPP0S=D;KH$1-=*D=%%#(+:F`]\
MCOO+_>%]@_9+W&YOYM]E^2(N9?O)7>F*7=+F%Y[3:C&BQ#Z5'4`S`+D4(!R6
MST-.6>1.=N?+&RF]T]R^FY:4ZX]JMWI&U3J4W4@S*17AV@<,]6D_&#OC:]%M
MK;W7NY&RU'NRNS#8_'4J8&6GQ"0SB&''4E$\,:4])1TT<?C1"/0JBY)Y]K?N
M7??"Y7N-AV7V[]S=XWJ?W9WG>Y/U)[>21)I+EE$?ZP[444TZ2%"`"@IU)6_\
MN/"3-MMO#'MD,(`5"%"JHI0+\A]O1]/?57H%=>]^Z]U[W[KW57W\YJFJJO\`
MEJ?*&GHJ2KKJF7:V`6*EH:::KJI6_OKMLD14].DDTA`!)L#8"_LQVH@;A;$G
M%3_@/44^]R/)[8<TQQH6<QQ@`"I_MH^JA_\`A,'A\C2;!^4E-F\)DJ"*IW9M
M&U/F<554<=2HV]3!M,5=!&LZCZ'@^S+?V#-`5.?]CJ)/NP6TD5CS.D\>#(O$
M8\_RZVJ,?A\3B%=,5B\=C$E;5(F/HJ:B61KDZG6FBC#M<_4^PZ23Q/65L<44
M51%$J@^@`_P=./O73G466AH9FUS4=+*_^KEIX9&_Y*9"?:"?:]LNG\6YVZ"2
M3U:-&/[2">K!W445R!]O4A$2-0L:*BCZ*BA5'^L%`'M9'''$H2*-50>0``_8
M.JDDY)SUYE5P5=593]58!@?]<&X/O;HDBE)$#(>((J/V'KU2,CKI(XXP1'&D
M8/)"*J@G_$*!?W2*"&&HAA5`>.D`5_9ULDGB>O211S(T4T:2QN+/'(BNC#^C
M(P*L/]?V[U4@,*$5'6&GHJ.DU?:4E-2Z[:_MX(H=5OIJ\:+JM_C[]4GB>JJB
M)70@'V"G6=T21&CD19$<%71U#(RG@JRL"&!'X/OW5B`001CJ/3T-%2%FI:.E
MIF<69J>GAA+`?0,8T4D#_'WZI]>JK&B91`#\A3KE54E)70/35M+3UE-(+24]
M5#'402#^CQ2J\;#_`%Q[\"1P/6V1'4JZ@KZ$5'4:DP^)H*5J*AQ>.HJ)^7I*
M2BIJ:E<_6[4\,21-S_4>]DD\3U5(8D4HD2A#Y``#]G4FGI*2D#+2TM/3*Y!=
M:>&.$,0+`L(U4,0/Z^_5)XGJRHB5"(`/D*=0:[`8+*2QSY/"XG(S1&\4U=CJ
M.KEB/]8Y*B&1T/\`K$>_!F'`GIN2W@E(:6%&8>H!_P`(ZEOCZ"6**"2BI)((
M?\S"]-"\47X_:C9"D?']`/?JGUZN8XR`IC!4<!0=9H88:>-8H(HH(E_3'#&L
M4:_\%1`JC_;>]=655444`#Y=?__6W/\`YU8'OC/_`!;[4@^,U5X.\<=B:;-[
M`IB\:)E\KB*^FK),+)Y62)ER5&DD85F4,Q`N/:FS:%;A/''Z7GT$N>8-\N.5
M]T7EMR-Z50T0%*L58$KG!J*X/'A7JGG9G\V7^87E\>-J4G\I[LZL[D]-)G)(
M\D<-LZJRD*&)\A+7S4/ECC\@+NA9PJW`<CV9&PLOB:^I'^1_R]0_;>ZON(\7
MTL7M?))O'!J,ZH2/,UCJ/L)H/XNE:GQA_F[_`#D8'Y3?(3"_#;IC)J\5;U-\
M>S)5=@Y7%3V%7B]R;H?[-8UJ(P4U+-)HOJ"G\T\?;[4?H1^)+ZGA]HK7_`.E
MR<M^['.Y_P"11O:;1LS<8+8DRLIXJY&D>N=;#^CZVG_$SX(?&?X6;<FPG1O7
MU%B,KDTC.Y=\Y=VS>_-UU*^J2JSVYJX29"J:68E]`98P3P/9?<74UT?U6JOI
MY=2ARIR+RWR9;F'9+`+,WQRMW2OY]SG-*\`*`>G1N!CZ$7_R*EY)8DT\1)+&
MY))0DDD^R8;/M(K3:[?C7^S3S_+H9>))_&?V]<EHJ-&5TI*9'4W5E@B5E(^A
M5@@((]W3:]MB=9(]N@6134$1H"#Z@@5'6B[G!<T^WJ3[7=5Z][]U[KWOW7NL
M<L,-1&T,\4<T3BSQ2HLD;@$&S(X96%Q^1[]PX=:(#`A@".L5/14=&&%)24U*
M'(+BG@B@#D"P+")%U$#^OOU>M*B)70@'V"G4GW[JW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7_U]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
C?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
